{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vincristine&page=2", "query": { "intervention": "Vincristine", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vincristine&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-26T05:45:59.302Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01321008", "title": "Stage I/II Nasal NK Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Radiation", "type": "RADIATION" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2011-05", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2015-02-05", "last_synced_at": "2026-09-26T05:45:59.302Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01321008" }, { "nct_id": "NCT01222780", "title": "To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma", "Neuroblastoma", "Wilms Tumor", "Leukemia", "Lymphoma", "Brain Tumors" ], "interventions": [ { "name": "Marqibo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acrotech Biopharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "2 Years to 20 Years" }, "enrollment_count": 22, "start_date": "2010-09", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2020-01-18", "last_synced_at": "2026-09-26T05:45:59.302Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01222780" }, { "nct_id": "NCT00877110", "title": "Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma", "Bone Marrow, Sympathetic Nervous System" ], "interventions": [ { "name": "cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 71, "start_date": "2009-04-02", "completion_date": "2019-01-07", "has_results": false, "last_update_posted_date": "2019-01-10", "last_synced_at": "2026-09-26T05:45:59.302Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00877110" }, { "nct_id": "NCT01569750", "title": "A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CD20-positive B-cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Part 1, Cohort 1", "type": "DRUG" }, { "name": "Part 1, Cohort 2", "type": "DRUG" }, { "name": "Part 1, Cohort 3", "type": "DRUG" }, { "name": "Part 2, Cohort 1", "type": "DRUG" }, { "name": "Part 2, Cohort 2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2012-06-14", "completion_date": "2014-09-04", "has_results": false, "last_update_posted_date": "2017-08-22", "last_synced_at": "2026-09-26T05:45:59.302Z", "location_count": 4, "location_summary": "New York, New York • Rochester, New York • Nashville, Tennessee + 1 more", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Rochester", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01569750" }, { "nct_id": "NCT00476190", "title": "ALL Adult Consortium Trial: Adult ALL Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Methylprednisone", "type": "DRUG" }, { "name": "Hydrocortisone Sodium Succinate", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "6-MP", "type": "DRUG" }, { "name": "PEG-Asparaginase", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "PROCEDURE" }, { "name": "E. coli Asparaginase", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 112, "start_date": "2007-04", "completion_date": "2020-03", "has_results": true, "last_update_posted_date": "2025-06-12", "last_synced_at": "2026-09-26T05:45:59.302Z", "location_count": 7, "location_summary": "Boston, Massachusetts • New York, New York • Columbus, Ohio + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00476190" }, { "nct_id": "NCT00618813", "title": "Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Ewing Sarcoma of Bone", "Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor" ], "interventions": [ { "name": "radiation therapy", "type": "OTHER" }, { "name": "therapeutic conventional surgery", "type": "OTHER" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 35, "start_date": "2008-03", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-09-25", "last_synced_at": "2026-09-26T05:45:59.302Z", "location_count": 1, "location_summary": "Monrovia, California", "locations": [ { "city": "Monrovia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00618813" }, { "nct_id": "NCT00376961", "title": "S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 68, "start_date": "2006-08", "completion_date": "2017-09", "has_results": true, "last_update_posted_date": "2017-11-06", "last_synced_at": "2026-09-26T05:45:59.302Z", "location_count": 147, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 95 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00376961" }, { "nct_id": "NCT01030900", "title": "Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Lymphoma", "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Campath", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "EPOCH", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2009-10-22", "completion_date": "2021-08-06", "has_results": true, "last_update_posted_date": "2022-10-06", "last_synced_at": "2026-09-26T05:45:59.302Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01030900" }, { "nct_id": "NCT00290498", "title": "Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "16 Years to 60 Years" }, "enrollment_count": 67, "start_date": "2005-08-01", "completion_date": "2017-08-11", "has_results": true, "last_update_posted_date": "2020-06-02", "last_synced_at": "2026-09-26T05:45:59.302Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00290498" }, { "nct_id": "NCT00337987", "title": "A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral T-Cell Lymphoma" ], "interventions": [ { "name": "Ontak", "type": "DRUG" }, { "name": "CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2005-11", "completion_date": "2008-01", "has_results": true, "last_update_posted_date": "2015-02-27", "last_synced_at": "2026-09-26T05:45:59.302Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00337987" } ] }